Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase I studies evaluate repurposed mibefradil with radiotherapy or chemotherapy in glioma patients

Dec. 4, 2015

Novel ADCs have a significant cytotoxic effect both in vitro and in vivo

Dec. 4, 2015

First-in-human results lead to phase II planning for ABTL-0812

Dec. 4, 2015

Phase II dose determined for tremelimumab plus gefitinib in EGFR-mutant NSCLC

Dec. 4, 2015

Pradigastat reduces liver fat in patients with nonalcoholic fatty liver disease

Dec. 3, 2015

Atea plans clinical development of new hepatitis C virus polymerase inhibitors

Dec. 3, 2015

FAK inhibitor GSK-2256098 reaches glioblastoma tumor tissue in patients

Dec. 3, 2015

S1P2 receptor antagonist shows promise for fibrosis

Dec. 3, 2015

First-in-class FGFR inhibitor demonstrates FGFR subtype selectivity

Dec. 2, 2015

Adding DNA-damaging properties to PARP inhibitor enhances potency

Dec. 2, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...